Anti cd4

Manufactured by Leica

Sourced in Germany

Anti-CD4 is a laboratory reagent used for the detection and enumeration of CD4+ T cells. It is a monoclonal antibody that specifically binds to the CD4 surface protein expressed on a subset of T lymphocytes. The core function of Anti-CD4 is to facilitate the identification and quantification of CD4+ T cells in various research and diagnostic applications.

Automatically generated - may contain errors

Lab products found in correlation

5 protocols using anti cd4

Immunological Antibody Characterization Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols

The table below describes the commercial antibodies used, their catalog numbers, and their company.
Western blot and immunofluorescence antibodies.

Anti-Alix (sc-49267)	(Santa Cruz Biotechnology)
Anti-β-actin (MA1-91399)	(Thermo Fisher Scientific)
Anti-β-actin (sc-47778)	(Santa Cruz Biotechnology)
Anti-CD4 (2009-09)	(Novocastra)
Anti-CD63 (sc-15363)	(Santa Cruz Biotechnology)
Anti-EEA1 (610456)	(BD Biosciences)
Anti-Flotillin1 (ab41927)	(Abcan)
Anti-GAPDH (G9545)	(Sigma-Aldrich)
Anti-GFP	Gift from R. Hedge (MRC)
Anti-ΗΑ (H3663)	(Sigma-Aldrich)
Anti-HLA-A (15240-1-AP)	(Proteintech)
Anti-IFITM1 (60074-1-Ig)	(Proteintech)
Anti-IFITM2 (66137-1-Ig)	(Proteintech)
Anti-IFITM3/2 (11714-1-AP)	(Proteintech)
Anti-Lat1 (sc-54229)	(Santa Cruz Biotechnology)
Anti-TfR (136800)	(Thermo Fisher Scientific)
Anti-Tsg101 (976126)	(BD Bioscencies)
Anti-Nef (2949)	(NIH AIDS Reagent Program)
Anti-Neurexin1 (ab77596)	(BD Bioscencies)
Anti-Syntenin1 (ab133267)	(Abcan)
Anti-IgG Mouse-HRP	(GE)
Anti-IgG Rabbit-HRP	(GE)
Anti-IgG Goat-HRP	(GE)
Anti-IgG Mouse-Alexa 594	(Thermo Fisher Scientific)
Anti-IgG Rabbit-Alexa 647	(Thermo Fisher Scientific)

da Silva-Januário M.E., da Costa C.S., Tavares L.A., Oliveira A.K., Januário Y.C., de Carvalho A.N., Cassiano M.H., Rodrigues R.L., Miller M.E., Palameta S., Arns C.W., Arruda E., Paes Leme A.F, & daSilva L.L. (2023). HIV-1 Nef Changes the Proteome of T Cells Extracellular Vesicles Depleting IFITMs and Other Antiviral Factors. Molecular & Cellular Proteomics : MCP, 22(12), 100676.

+ Open protocol

+ Expand

Skin Biopsy for Phage Id Challenge

Check if the same lab product or an alternative is used in the 5 most similar protocols

Patient 7 was chosen to undergo a skin biopsy of the site of phage Id challenge, since this patient displayed a positive Id-related delayed type hypersensitivity reaction and an Id-specific humoral response. Staining was performed with hematoxylin-eosin and anti-CD8 (Dako GmbH, Hamburg, Germany) and anti-CD4 (Novocastra, Berlin, Germany) antibodies for immunohistochemistry analysis.

Roehnisch T., Then C., Nagel W., Blumenthal C., Braciak T., Donzeau M., Böhm T., Flaig M., Bourquin C, & Oduncu F.S. (2014). Phage idiotype vaccination: first phase I/II clinical trial in patients with multiple myeloma. Journal of Translational Medicine, 12, 119.

+ Open protocol

+ Expand

Immunohistochemistry and Elastic Staining of FFPE Tissues

Check if the same lab product or an alternative is used in the 5 most similar protocols

FFPE tissues were sectioned at 5 mm thickness and analyzed by IHC and EVG staining. The following antibodies were used: anti-TP53 (Santa Cruz Biotechnology, Dallas, TX, USA, catalog number: sc-47698), anti-CDKN2A/p16 (Roche Diagnostics, Cat #6695221001), anti-SMAD4 (Santa Cruz Biotechnology, Cat #sc-7966), anti-CD4 (Leica Biosystems, Wetzlar, Germany, Cat #CD4-368-L-CE), anti-CD8 (Roche Diagnostics, Cat #5493846001), anti-FOXP3 (Abcam, Cambridge, UK, Cat #ab20034), anti-CD45RO (BioGenex Laboratories, San Ramon, CA, USA,Cat #AM113-5M), anti-CD68 (ProteinTech Illinois, USA, Cat #66231-2-Ig), anti-CD206 (ProteinTech Illinois, USA, Cat #60143-1-Ig) and anti-α-SMA (Santa Cruz Biotechnology, catalog number: sc-53142). EVG staining was performed using an Elastic Stain Kit (Abcam, Cat #ab150667) according to the manufacturer’s protocol.

Abe S., Masuda A., Matsumoto T., Inoue J., Toyama H., Sakai A., Kobayashi T., Tanaka T., Tsujimae M., Yamakawa K., Gonda M., Masuda S., Uemura H., Kohashi S., Inomata N., Nagao K., Harada Y., Miki M., Irie Y., Juri N., Ko T., Yokotani Y., Oka Y., Ota S., Kanzawa M., Itoh T., Imai T., Fukumoto T., Hara E, & Kodama Y. (2024). Impact of intratumoral microbiome on tumor immunity and prognosis in human pancreatic ductal adenocarcinoma. Journal of Gastroenterology, 59(3), 250-262.

+ Open protocol

+ Expand

Comprehensive Hematological and Immunological Profiling

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

CBC was measured by an automated blood count (Hemavet System 950FS). May-Grünwald-Giemsa staining (Thermo Fisher Scientific, catalog 22-050-272) was used to stain PB smears. Histological analyses were performed as previously described (83 (link)), and samples were stained with H&E.
The following antibodies were used for IHC analysis: anti-CD68 (Leica Biosystems, PA0273); anti-CD69 (Abcam, 202909); anti-Ki67 (Cell Signaling Technology, 12202S; Leica Biosystems, PA0230) anti-galectin/MAC2 (Abcam, ab76245); anti-CD3 (Cell Signaling Technology, 99940S); anti-CD4 (Leica Biosystems, PA0427); anti-CD8 (Leica Biosystems, PA0183); and anti-FOXP3 (Abcam, ab215206). For BM and liver fibrosis analyses, a reticulin staining kit (MilliporeSigma, HT102A-1KT) was used.
For plasma analyses, PB samples were collected in heparinized tubes and centrifuged, and plasma was frozen or directly assayed. Plasma was used for the cytokine array analyses (R&D Systems, ARY028); the ferritin ELISA kit (ALPCO, 41-FERMS-E01); the sCD25 ELISA kit (G-Biosciences, IT5809); and chemistry profiling (HESKA; catalog 6330, COMP/EWRAP).

Mas G., Man N., Nakata Y., Martinez-Caja C., Karl D., Beckedorff F., Tamiro F., Chen C., Duffort S., Itonaga H., Mookhtiar A.K., Kunkalla K., Valencia A.M., Collings C.K., Kadoch C., Vega F., Kogan S.C., Morey L., Bilbao D, & Nimer S.D. (2023). The SWI/SNF chromatin-remodeling subunit DPF2 facilitates NRF2-dependent antiinflammatory and antioxidant gene expression. The Journal of Clinical Investigation, 133(13), e158419.

+ Open protocol

+ Expand

SARS-CoV-2 Lung Histopathology and Immune Profiling

Check if the same lab product or an alternative is used in the 5 most similar protocols

Between August 2020 and March 2021, histological lung specimens were obtained from eight SARS-CoV-2-positive patients for antemortem evaluation after bronchoscopy and cryotransbronchial biopsy. The clinical records, radiological, and pathological findings were retrospectively compiled. Transbronchial biopsy specimens were available in all patients, taken from the most prominent areas of the interstitial ground-glass opacities. The mean number of lung biopsy fragments per case was three (range 2–4).
Biopsy specimens were fixed in 10% formalin, embedded in paraffin wax, and sectioned at 5 μm. Sections were stained with haematoxylin and eosin. Each biopsy specimen was evaluated semi-quantitatively for the following parameters: the presence or absence of reactive pneumocytes; alveolar macrophages; lymphocytes; neutrophils; plasma cells, fibroblastic foci; peribronchiolar inflammation; and viral cytopathic effect.
Immunohistochemical labelling was performed with antibodies directed against the following proteins: CD3 (anti-CD3; Leica Biosystems, UK); CD4 (anti-CD4; Leica Biosystems); CD8 (anti-CD8; Leica Biosystems); CD20 (anti-CD20; Leica Biosystems); and SARS-CoV-2 nucleocapsid protein.² (link) CD4 and CD8 staining were scored as percent-positive immune cell: 0, negative; 1, 1–30%; 2, 31–70%; and 3, 71–100% positive immune cell.

Puzyrenko A., Felix J.C., Ledeboer N.A., Sun Y., Rui H, & Sheinin Y. (2021). Cytotoxic CD8-positive T-lymphocyte infiltration in the lungs as a histological pattern of SARS-CoV-2 pneumonitis. Pathology, 54(4), 404-408.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!